CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
作者信息
Holzinger Astrid, Abken Hinrich
机构信息
Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
Clinic I Internal Medicine, University Hospital Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
出版信息
Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28.
Abstract
摘要
相似文献
1
CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.靶向实体瘤的嵌合抗原受体T细胞：癌胚抗原（CEA）被证明是一个安全的靶点。
Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28.
2
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.针对实体瘤的嵌合抗原受体 T 细胞（CAR-T）癌症免疫疗法面临的障碍。
Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11.
3
Armed T cells with CAR for cancer immunotherapy.用于癌症免疫治疗的嵌合抗原受体武装T细胞。
Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.
4
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.第一代癌胚抗原（CEACAM5）特异性嵌合抗原受体T细胞的临床疗效受到持久性差和短暂的预处理依赖性呼吸毒性的限制。
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.
5
Strategies to genetically engineer T cells for cancer immunotherapy.用于癌症免疫治疗的T细胞基因工程策略。
Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2.
6
CARs in the Lead Against Multiple Myeloma.嵌合抗原受体在对抗多发性骨髓瘤中领先。
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2.
7
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.儿童实体瘤中CAR-T细胞在急性淋巴细胞白血病之外的应用前景
Am Soc Clin Oncol Educ Book. 2018 May 23;38:830-837. doi: 10.1200/EDBK_200773.
8
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.用于癌症过继性免疫治疗的嵌合T细胞：利用所学知识规划未来
Immunotherapy. 2009 Nov;1(6):905-12. doi: 10.2217/imt.09.69.
9
Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.嵌合抗原受体修饰 T 细胞的过继性 T 细胞免疫疗法治疗癌症。
Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):165-78. doi: 10.1007/s00005-010-0074-1. Epub 2010 Apr 6.
10
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.肿瘤抗原和受体密度调节靶向间变性淋巴瘤激酶的嵌合抗原受体的疗效。
Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.
引用本文的文献
1
Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions.实体瘤CAR-T细胞疗法的进展与挑战：抗原靶点、策略及未来方向的全面综述
Cancer Cell Int. 2025 Aug 23;25(1):313. doi: 10.1186/s12935-025-03938-0.
2
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges.胃肠道癌症中的嵌合抗原受体T细胞疗法：当前临床试验及克服挑战的策略
Nat Rev Gastroenterol Hepatol. 2025 Apr 14. doi: 10.1038/s41575-025-01062-y.
3
Immunotherapy in gastrointestinal cancers: current strategies and future directions - a literature review.胃肠道癌症的免疫疗法：当前策略与未来方向——文献综述
Ann Med Surg (Lond). 2025 Jan 9;87(1):151-160. doi: 10.1097/MS9.0000000000002757. eCollection 2025 Jan.
4
Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors.癌胚抗原在人类肿瘤中的表达：一项对13725例肿瘤的组织芯片研究
Cancers (Basel). 2024 Dec 3;16(23):4052. doi: 10.3390/cancers16234052.
5
CAR T cells in solid tumors and metastasis: paving the way forward.实体瘤和转移瘤中的嵌合抗原受体 T 细胞：铺平前进之路。
Cancer Metastasis Rev. 2024 Dec;43(4):1279-1296. doi: 10.1007/s10555-024-10213-7. Epub 2024 Sep 24.
6
CAR-T cell therapy in advanced thyroid cancer: from basic to clinical.嵌合抗原受体 T 细胞疗法治疗晚期甲状腺癌：从基础到临床。
Front Immunol. 2024 Jun 7;15:1411300. doi: 10.3389/fimmu.2024.1411300. eCollection 2024.
7
Car T Cells in Solid Tumors: Overcoming Obstacles.实体瘤中的嵌合抗原受体T细胞：克服障碍
Int J Mol Sci. 2024 Apr 10;25(8):4170. doi: 10.3390/ijms25084170.
8
Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.使用 AND 门适配器 RevCAR T 细胞靶向结直肠癌细胞。
Front Immunol. 2023 Dec 15;14:1302354. doi: 10.3389/fimmu.2023.1302354. eCollection 2023.
9
"Hurdles race for CAR T-cell therapy in digestive tract cancer".“CAR T 细胞疗法在消化道癌症治疗中面临的障碍”。
Immunol Rev. 2023 Nov;320(1):100-119. doi: 10.1111/imr.13273. Epub 2023 Sep 11.
10
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.嵌合抗原受体 T 细胞疗法在结直肠癌和浸润性乳腺癌中的最新临床观点和挑战。
Arch Immunol Ther Exp (Warsz). 2023 Aug 11;71(1):19. doi: 10.1007/s00005-023-00684-x.
本文引用的文献
1
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.第一代癌胚抗原（CEACAM5）特异性嵌合抗原受体T细胞的临床疗效受到持久性差和短暂的预处理依赖性呼吸毒性的限制。
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.
2
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers.靶向癌胚抗原的嵌合抗原受体T细胞疗法用于转移性结直肠癌的I期剂量递增试验。
Mol Ther. 2017 May 3;25(5):1248-1258. doi: 10.1016/j.ymthe.2017.03.010. Epub 2017 Mar 31.
3
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.用于CEA阳性肝转移的肝内动脉嵌合抗原受体修饰T细胞疗法的I期肝转移免疫治疗研究
Clin Cancer Res. 2015 Jul 15;21(14):3149-59. doi: 10.1158/1078-0432.CCR-14-1421. Epub 2015 Apr 7.
4
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.针对癌胚抗原的 T 细胞可以介导转移性结直肠癌的消退，但会引起严重的短暂性结肠炎。
Mol Ther. 2011 Mar;19(3):620-6. doi: 10.1038/mt.2010.272. Epub 2010 Dec 14.
Zotero 插件